Investigation Report on China’s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) Market, 2021-2025 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Investigation Report on China’s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) 2021-2025” report has been added to ResearchAndMarkets.com’s offering.

Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) is an effective drug for the prevention and treatment of neutropenia or deficiency caused by tumor radiotherapy or chemotherapy. Its product was first developed by Amgen in the United States.

In 2012, PEG-rhG-CSF was approved in China. By 2020, the main manufacturers of PEG-rhG-CSF in China are Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd. and Qilu Pharmaceutical Co., Ltd.

According to the market research, the sales of PEG-rhG-CSF in the Chinese market have increased year by year from 2016 to 2020. Among them, the sales growth in 2017 was the most obvious, from CNY126 million in 2016 to CNY449 million in 2017, with an annual growth rate of 256.08%.

The main reason for the sharp increase is that PEG-rhG-CSF was included in China Medical Insurance in 2017 and the approval of indication was leukemia. The price reduction led to a large increase in sales. The CAGR of sales of PEG-rhG-CSF is about 97.58% from 2016 to 2020.

The analyst analyzes that the sales volume of PEG-rhG-CSF will keep a growth trend from 2021 to 2025 due to the rapid increase in the number of patients. In China, about 40,000 leukemia patients are newly diagnosed every year. This situation led to a growth in the sales volume of PEG-rhG-CSF, which has the advantages of convenience, stability, high efficiency, and approval of indications.

In addition, due to the use of PEG-rhG-CSF for non-medullary malignant tumors, the number of indications approved for China’s medical insurance is likely to rise, and the sales and the sales volume will also have the potential to grow.

Topics Covered:

• The impact of COVID-19 on China’s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market
• Sales value of China’s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) 2016-2020
• Competitive landscape of China’s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market
• Prices of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) in China
• Prices of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) in China by regions and manufacturers
• Analysis of factors affecting the development of China’s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market
• Prospect of China’s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF) market from 2021 to 2025

Key Topics Covered:

1 Relevant Concepts of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rhG-CSF)

1.1 Indications for Pegylated Recombinant Human Granulocyte Colony Stimulating Factor

1.2 Development of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor in China

1.3 Governmental Approval of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor in China

1.4 The Impact of COVID-19 on Pegylated Recombinant Human Granulocyte Colony Stimulating Factor sales in China

2 Sales of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor in China, 2016-2020

2.1 Sales Value of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor

2.1.1 Overall Sales Value

2.1.2 Sales Value by Regions

2.2 Sales Volume of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Regions

2.3 Sales of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor by Dosage Form in China, 2016-2020

2.3.1 Injection

2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Manufacturers in China, 2016-2020

3.1 Analysis of Market Share of Major Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales Volume

3.2 Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd.

3.2.1 Enterprise Profile

3.2.2 Sales of Jinyouli (Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd.’s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor) in China

3.3 Qilu Pharmaceutical Co., Ltd.

3.3.1 Enterprise Profile

3.3.2 Sales of Xinruibai (Qilu Pharmaceutical Co., Ltd.’s Pegylated Recombinant Human Granulocyte Colony Stimulating Factor) in China

4 Prices of Pegylated Recombinant Human Granulocyte Colony Stimulating Factor for Different Manufacturers in China, 2020-2021

4.1 Shiyao Group Baike (Shandong) biopharmaceutical Co., Ltd. (Yinish)

4.2 Qilu Pharmaceutical Co., Ltd. (Xinruibai)

5 Prospect of Chinese Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market, 2021-2025

5.1 Influential Factors of Chinese Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market Development

5.1.1 The Impact of COVID-19 on Chinese Pegylated Recombinant Human Granulocyte Colony Stimulating Factor Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

Companies Mentioned

• Shiyao Group Baike biopharmaceutical Co., Ltd.
• Qilu Pharmaceutical Co., Ltd

For more information about this report visit https://www.researchandmarkets.com/r/5flris

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900